Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Endocrinol.

Sec. Cardiovascular Endocrinology

This article is part of the Research TopicCommunity Series in: Clinical and Genetic Determinants of Diabetes and Complications - Volume IIView all articles

Fasting Glucagon as an Independent risk indicator for CAD in Patient with Type 2 Diabetes

Provisionally accepted
Linlin  KongLinlin KongLina  ChangLina ChangJiamin  NieJiamin NieYian  GuYian GuXin  WangXin WangSiyu  YanSiyu YanWantong  HanWantong HanHequn  SangHequn SangShaofang  TangShaofang TangMing  LiuMing LiuQing  HeQing He*
  • Tianjin Medical University General Hospital, Tianjin, China

The final, formatted version of the article will be published soon.

Objective: To investigate the association between fasting glucagon levels and coronary artery disease (CAD) risk in patients with Type 2 Diabetes Mellitus (T2DM). Methods: This cross-sectional study enrolled 1,739 hospitalized T2DM patients, categorized into T2DM alone and T2DM with CAD (T2DM&CAD) groups. Fasting glucagon levels and clinical characteristics were collected. Multivariable logistic regression models were used to assess this association, with progressive adjustment for confounders. Results: In female patients, fasting glucagon levels were significantly higher in the T2DM&CAD group than in the T2DM alone group (13.33 vs. 11.52 pmol/L, P < 0.01). After full adjustment, each 1-SD increase was associated with a 49.2% higher CAD risk (OR: 1.492; 95% CI: 1.099-2.026; P < 0.05). No significant association was found in male patients. Conclusion: Elevated fasting glucagon is an independent risk indicator for CAD in women with T2DM, but not in men. These findings highlight the potential value of glucagon monitoring in T2DM management, especially for women, and support exploring glucagon-pathway-targeted therapies to reduce cardiovascular complications.

Keywords: Cardiometabolic risk, complication, Coronary Artery Disease, Glucagon, type 2 diabetes mellitus

Received: 19 Nov 2025; Accepted: 27 Nov 2025.

Copyright: © 2025 Kong, Chang, Nie, Gu, Wang, Yan, Han, Sang, Tang, Liu and He. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Qing He

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.